Acute Invasive Aspergillosis Treatment Market Competitive Landscape 2020, Global Analysis by Size, Growth Rate, Key Trends, drug type, diagnosis, Treatment and Regional Forecast 2026
SEATTLE, March 24, 2021, (PHARMIWEB) — Global Acute Invasive Aspergillosis Treatment Market – Insights
Acute Invasive Aspergillosis (IA) is a rare, opportunistic, and serious infection caused by fungi of the genus Aspergillus. The fungi is found on decaying vegetation and dead leaves. The prevalence of the disease is very low. It affects immunocompromised patients or those suffering from lung diseases. Although majority of the population comes in contact with the fungi, not everyone is vulnerable to IA or acute IA. Aspergillosis can be divided into various types such as invasive aspergillosis, chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, allergic aspergillus sinusitis, aspergilloma, and cutaneous aspergillosis. Weakened immune system, low white blood cell count, presence of lung cavities, asthma or cystic fibrosis, and long-term corticosteroid therapy are some of the risk factors responsible for the development of invasive aspergillosis infection. Voriconazole, Capsofungin, and Amphotericin B are some of the drugs sold for the treatment of aspergillus infection.
Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/1520
Global Acute Invasive Aspergillosis Treatment Market: Drivers
Increasing number of solid organ transplants is expected to boost growth of the global acute invasive aspergillosis treatment market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, the epidemiology of invasive aspergillus infection relies upon increasing number of solid organ transplants, stem cell transplant, and newer immunosuppressive agents. According to Organ Procurement and Transplantation Network (OPTN), around 8,500 organ transplants were performed in 2018 and the number is expected to grow in the near future. Patients undergoing organ transplant procedure are often prescribed immunosuppressant medications. This may lead to high vulnerability to acute IA.
Increasing prevalence of AIDS is also expected to boost growth of the market as patients in advanced stages of AIDS are at risk of acquiring acute IA. For instance, according to the World Health Organization (WHO), around 36.7 million people were found suffering from HIV in 2016. Increase use of corticosteroids may adversely impact the immune system, which may further lead to high risk of acquiring acute IA, thereby contributing to growth of the market. According to British Infection Association, the high risk population for invasive aspergillosis includes patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT), autologous HSCT patients, solid organ transplant patients as well as AIDS patients, patients suffering from acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, non-Hodgkin lymphoma, and myeloma patients.
Exclusive offer!!! Purchase the report at a discounted rate!!!
Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Quick Buy – Acute Invasive Aspergillosis Treatment Market Research Report: https://bit.ly/3f6QqcU
Increasing prevalence of cancer is also expected to boost growth of the global acute invasive aspergillosis treatment market. For instance, according to WHO, cancer is the second-leading cause of death globally, and the disease caused 8.8 million deaths in 2015. Increasing approval of drugs for the treatment of acute IA is expected to propel growth of the market. For instance, in 2015, Isavuconazonium, a prodrug form of Isavuconazole was approved by the U.S. FDA. Astellas Pharma US, Inc. markets Isavuconazonium under the brand name Cresemba. Astellas Pharma partnered with Basilea Pharmaceutica International Ltd. for license, co-development, and co-promotion of Isavuconazole (Cresemba), in 2010. In 2014, Basilea Pharmaceutica International Ltd. received full rights to sell Isavuconazole in all markets outside of the U.S. and Canada and Astellas Pharma was responsible for the U.S. and Canada markets. Moreover, Basilea Pharmaceutica Ltd. partnered with Asahi Kasei Pharma for Isavuconazole development, licensing, and marketing in Japan (responsibility of Asahi Kasei), in 2016.
Moreover, patent expiry is expected to offer lucrative growth opportunities for the market players. For instance, the drug Cresemba will expire in 2020, which may aid in price drop and increase in sales volume as generic manufacturers enter the market. Manufacturers such as Amneal Pharmaceuticals, Sandoz Inc., Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals, and Glenmark Pharmaceuticals Ltd. offer generic versions of antifungal medications.
Global Acute Invasive Aspergillosis Treatment Market: Restraints
Increasing cases of resistance to antifungal medications is expected to hinder growth of the global acute invasive aspergillosis treatment market.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/acute-invasive-aspergillosis-treatment-market-1520
Global Acute Invasive Aspergillosis Treatment Market: Competitive Landscape
Key players in the market are focused on R&D of novel antifungal therapies to expand their product portfolio. For instance, F2G, a U.K.-based biotechnology company, is focused on R&D of novel drugs for the treatment of serious fungal diseases such as acute IA.
Major players operating in the global acute invasive aspergillosis treatment market include, Abbott laboratories, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Mylan Pharmaceuticals, Inc., Novartis AG, AstraZeneca Plc, Pfizer, Inc., Takeda Pharmaceutical Company Ltd., Astellas, and Basilea Pharmaceutica International Ltd.
Acute Invasive Aspergillosis Treatment Market Taxonomy-
Global acute invasive aspergillosis treatment market is segmented on the basis of drug type, distribution channel, and geography.
By Drug Type-
- Amphotericin B
By Distribution Channel-
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire